COVID-19

Authors: Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, D’Andrea V, Trentini F, Ajelli M, Poletti P, Merler S.

Published in: JAMA Network Open

Authors: Redfern A, van der Zalm MM, Lishman J, Goussard P, Smit L, Dagan R, Barday M, Mare M, Claassen M, Van Zyl G, Rabie H, Verhagen LM.

Published in: The Pediatric Infectious Disease Journal

Authors: Van der Zalm MM, Donà D, Rabie H.

Published in: Current Opinions in Pediatrics

Authors: Sabatino J, Di Chiara C, Di Candia A, Sirico D, Donà D, Fumanelli J, Basso A, Pogacnik P, Cuppini E, Romano LR, Castaldi B, Reffo E, Cerutti A, Biffanti R, Cozzani S, Giaquinto C, Di Salvo G.

Published in: Journal of Clinical Medicine

Authors: Minotti C, Mengato D, De Pieri M, Trivellato S, Francavilla A, Di Chiara C, Liberati C, Mattera R, Biffi A, Giaquinto C, Venturini F, Donà D.

Published in: Viruses

Authors: De Meijere G, Valdano E, Castellano C, Debin M, Kengne-Kuetche C, Turbelin C, Noël H, Weitz J, Paolotti D, Hermans L, Hens N, Colizza V.

Published in: The Lancet Regional Health – Europe

Authors: Westerhof I, de Hoog M, Ieven M, Lammens C, van Beek J, Rozhnova G, Eggink D, Euser S, Wildenbeest J, Duijts L, van Houten M, Goossens H, Giaquinto C, Bruijning-Verhagen P.

Published in: International Journal of Infectious Diseases

Authors: Donà D, Montagnani C, Di Chiara C, Venturini E, Galli L, Lo Vecchio A, Denina M, Olivini N, Bruzzese E, Campana A, Giacchero R, Salvini F, Meini A, Ponzoni M, Trapani S, Rossi E, Lombardi MH, Badolato R, Pierri L, Pruccoli G, Rossin S, Colomba C, Cazzato S, Pacati I, Nicolini G, Pierantoni L, Bianchini S, Krzysztofiak A, Garazzino S, Giaquinto C, Castelli Gattinara G

Published in: Viruses

Authors: Torneri A, Willem L, Colizza V, Kremer C, Meuris C, Darcis G, Hens N, Libin PJK.

Published in: eLife

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.

The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.

This is one of the first large observational studies that uses Real-World Data evaluate the effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine in children aged 5-11 against the Omicron variant.

Authors: Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N.

Published in: The New England Journal of Medicine

Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.

The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.

Authors: Pham TM, Westerhof I, Bootsma MCJ, Kretzschmar ME, Rozhnova G, Bruijning-Verhagen P.

Published in: MedRxiv

Authors: Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Donà D, Padoan A, Di Chiara C, Pezzani MD, Cosma C, Napolitan A, Quaranta EG, Giussani E, Fusaro A, Pascarella M, Aita A, Liberati C, Lorusso A, Monne I, De Rossi A, Basso D, Porru S, Ricci A, Terregino C, Plebani M, Tacconelli E*, Giaquinto C*, Bonfante F*.

Published in: Lancet Preprints

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus

The RBDCOV project, in which Penta is a partner, started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people, after the Spanish Agency for Medicines and Health Products (AEMPS) authorised it on 9 May. This clinical trial will determine whether an additional dose of HIPRA’s Covid-19 vaccine can generate an immune response in people living with immune system disorders,

Authors: Colosi E, Bassignana G, Contreras DA, Poirier C, Boëlle PY, Cauchemez S, Yazdanpanah Y, Lina B, Fontanet A, Barrat A, Colizza V

Published in: The Lancet

Authors: Di Chiara C, Mengato D, De Pieri M, Longo G, Benetti E, Venturini F, Giaquinto C and Donà D.

Published in: Children

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                

“RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA.